Mesoblast Limited


MELBOURNE, Australia, November 8, 2010 - Regenerative medicine company, Mesoblast Limited (ASX: MSB; USADR: MBLTY), today announced that its United States associate company, Angioblast Systems, has been awarded US$1.2 million in grants under the United States Government's Qualifying Therapeutic Discovery Project (QTDP) program.

MELBOURNE, Australia, July 12, 2010 - Australian regenerative medicine company, Mesoblast Limited (ASX: MSB; ADR: MBLTY), today announced that based on positive results from its bone marrow transplant clinical trial conducted at the University of Texas MD Anderson Cancer Center, a formal meeting has been scheduled with the United States Food and Drug Administration (FDA) to discuss a proposed Phase 3 clinical trial program.
Older News
S M T W T F S
26 27 28 29 30 31 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
Copyright© 2011 The Gaea Times